The Covid-19 pandemic has restricted the movement of people, confining them in their homes, caused severe trauma and stress in the form of sadness and loneliness and has affected the mental health of individuals. As a result, in many countries, people are facing medical conditions like depression and anxiety. The psychedelic drugs market with major potential for treatment of mental illnesses is likely to see more demand and hence likely to attract major investments in the near future.
Global Psychedelic Drugs Market was valued at USD 3.8 billion in the year 2020. The Psychedelic Drugs market is growing rapidly due to the increasing prevalence of depression and other mental disorders worldwide. The need for handling environmental stress and enhanced and better quality of lifestyle is acting as a driver for the Psychedelic Drugs market. The treatment for psychedelic drugs dependency is expected to boost psychedelic market growth.
In addition, rising research and development activities in psychedelic therapeutics categories across the world have supported industrial development significantly. Companies are aggressively investing in R&D activities to develop novel psychedelic treatment molecules with minimal side effects associated with these products. This has further resulted in a strong platform for the further growth of the psychedelic drug industry during the forecast period.
The North America region dominates the psychedelic drugs market. In North America, growing awareness of mental health disorders such as depression and stress is expected to boost the psychedelic drug market growth. Social elements such as economic stress, the partition of family-oriented supporting structures, exacerbating environmental conditions are further estimated to accelerate market growth during forecast period.
Scope of the Report
Key Target Audience
Global Psychedelic Drugs Market was valued at USD 3.8 billion in the year 2020. The Psychedelic Drugs market is growing rapidly due to the increasing prevalence of depression and other mental disorders worldwide. The need for handling environmental stress and enhanced and better quality of lifestyle is acting as a driver for the Psychedelic Drugs market. The treatment for psychedelic drugs dependency is expected to boost psychedelic market growth.
In addition, rising research and development activities in psychedelic therapeutics categories across the world have supported industrial development significantly. Companies are aggressively investing in R&D activities to develop novel psychedelic treatment molecules with minimal side effects associated with these products. This has further resulted in a strong platform for the further growth of the psychedelic drug industry during the forecast period.
The North America region dominates the psychedelic drugs market. In North America, growing awareness of mental health disorders such as depression and stress is expected to boost the psychedelic drug market growth. Social elements such as economic stress, the partition of family-oriented supporting structures, exacerbating environmental conditions are further estimated to accelerate market growth during forecast period.
Scope of the Report
- The report presents the analysis of Psychedelic Drugs Market for the historical period of 2016-2020 and the forecast period of 2021-2026.
- The report analyses Psychedelic Drugs Market by Route of Administration (Oral, Intranasal, Intravenous, Others)
- The report further assesses the Psychedelic Drugs Market by Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin, Others)
- The report further assesses the Psychedelic Drugs Market by Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
- The Global Psychedelic Drugs has been analysed By Region (North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, Italy, Spain, United Kingdom, China, Japan, India)
- The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions and Product Launch. Also, the attractiveness of the market has been presented By Region, By Route of Administration, By Drug and By Distribution Channel. Additionally, trends, drivers and challenges of the industry has been analysed in the report.
- The companies analysed in the report include Johnson & Johnson, Pfizer, AbbVie Inc., Jazz Pharmaceuticals, NUMINUS WELLNESS INC WS, COMPASS Pathways PLC, Mindset Pharma, Mydecine Innovations Group, TRYP Therapeutics Inc, MindMed and Cybin Inc.
Key Target Audience
- Pharmaceutical Companies
- Biotechnology Companies
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Government and Research Organisations
Table of Contents
1. Report Scope and Methodology1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Global Psychedelic Drugs Market Product Outlook
4. Global Psychedelic Drugs Market: An Analysis
4.1 Market Size, By Value, Year 2016-2026
4.2 COVID-19 Impact on Psychedelic Drugs Market
5. Global Psychedelic Drugs Market Segmentation By Route of Administration (By Value)
5.1 Competitive Scenario of Global Psychedelic Drugs Market: By Route of Administration
5.2 Oral Market Size and Forecast (2016-2026)
5.3 Intranasal Market Size and Forecast (2016-2026)
5.4 Intravenous Market Size and Forecast (2016-2026)
5.5 Others Market Size and Forecast (2016-2026)
6. Global Psychedelic Drugs Market Segmentation By Drug (By Value)
6.1 Competitive Scenario of Global Psychedelic Drugs Market: By Drug
6.2 Gamma-hydroxybutyrate Market Size and Forecast (2016-2026)
6.3 Ketamine Market Size and Forecast (2016-2026)
6.4 Psilocybin Market Size and Forecast (2016-2026)
6.5 MDMA Market Size and Forecast (2016-2026)
6.6 Others Market Size and Forecast (2016-2026)
7. Global Psychedelic Drugs Market Segmentation By Distribution Channel (By Value)
7.1 Competitive Scenario of Global Psychedelic Drugs Market: By Distribution Channel
7.2 Hospitals Pharmacy Market Size and Forecast (2016-2026)
7.3 Retail Pharmacy Market Size and Forecast (2016-2026)
7.4 Online Pharmacy Market Size and Forecast (2016-2026)
8. Global Psychedelic Drugs Market: Regional Analysis
8.1 Competitive Scenario of Global Psychedelic Drugs Market: By Region
9. North America Psychedelic Drugs Market: An Analysis (2016-2026)
9.1 North America Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
9.2 North America Psychedelic Drugs Market - Prominent Companies
9.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)
9.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)
9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)
9.6 North America Psychedelic Drugs Market: Country Analysis
9.7 Market Opportunity Chart of North America Psychedelic Drugs Market - By Country, By Value (Year-2026)
9.8 Competitive Scenario of North America- By Country
9.9 United States Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
9.10 United States Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
9.11 Canada Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
9.12 Canada Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10. Europe Psychedelic Drugs Market: An Analysis (2016-2026)
10.1 Europe Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.2 Europe Psychedelic Drugs Market - Prominent Companies
10.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)
10.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)
10.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)
10.6 Europe Psychedelic Drugs Market: Country Analysis
10.7 Market Opportunity Chart of Europe Psychedelic Drugs Market - By Country, By Value (Year-2026)
10.8 Competitive Scenario of Europe- By Country
10.9 Germany Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.10 Germany Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.11 United Kingdom Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.12 United Kingdom Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.13 France Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.14 France Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.15 Italy Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.16 Italy Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.17 Spain Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.18 Spain Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
11. Asia Pacific Psychedelic Drugs Market: An Analysis (2016-2026)
11.1 Asia Pacific Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.2 Asia Pacific Psychedelic Drugs Market - Prominent Companies
11.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)
11.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)
11.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)
11.6 Asia Pacific Psychedelic Drugs Market: Country Analysis
11.7 Market Opportunity Chart of Asia Pacific Psychedelic Drugs Market - By Country, By Value (Year-2026)
11.8 Competitive Scenario of Asia Pacific- By Country
11.9 China Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.10 China Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
11.11 India Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.12 India Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
11.13 Japan Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.14 Japan Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
12. Global Psychedelic Drugs Market Dynamics
12.1 Global Psychedelic Drugs Market Drivers
12.2 Global Psychedelic Drugs Market Restraints
12.3 Global Psychedelic Drugs Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.1.1 Market Attractiveness Chart of Global Psychedelic Drugs Market - By Drug, By Value (Year-2026)
13.1.2 Market Attractiveness Chart of Global Psychedelic Drugs Market - By Route of Administration, By Value (Year-2026)
13.1.3 Market Attractiveness Chart of Global Psychedelic Drugs Market - By Distribution Channel, By Value (Year-2026)
13.1.4 Market Attractiveness Chart of Global Psychedelic Drugs Market - By Region, By Value (Year-2026)
13.2 Strategic Analysis
13.2.1 Product approvals
13.2.2 Mergers and Acquisitions
14. Competitive Landscape
14.1 Market Share Analysis
15. Psychedelic Drugs Pipeline Development
16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 Johnson & Johnson
16.2 Pfizer
16.3 AbbVie Inc.
16.4 Jazz Pharmaceuticals
16.5 NUMINUS WELLNESS INC WS
16.6 COMPASS Pathways PLC
16.7 Mindset Pharma
16.8 Mydecine Innovations Group
16.9 TRYP Therapeutics Inc
16.10 MindMed
16.11 Cybin Inc.List of Figures
Figure 1: Global Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Share of Adults Reporting symptom of Anxiety or Depressive Disorder during COVID - 19 pandemic
Figure 3: Share of Adults Reporting Symptom of Anxiety and / or Depressive Disorder during COVID - 19 pandemic , by age
Figure 4: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 7: Health Care Spending (USD Billion) , 2017 and 2022
Figure 8: Number of persons aged 60 or above by region , (in millions) , in 2018
Figure 9: Number of individuals with Alzheimerís / Dementia Disease in million , 2018 - 2050
Figure 10: Prevalence of Migraine, (in Billion), in 2014 - 2019
Figure 11: Global Mental Health Disorders (People in Millions)
Figure 12: Global Mental Health Disorder Prevalence 2017
Figure 13: Companies developing psychedelic treatments for mental health disorders grouped by headquarters location
Figure 14: Psychedelic Therapeutics Distribution by target Therapeutics Area
Figure 15: Global Psychedelic Drugs Market, By Route of Administration, 2020, 2026
Figure 16: Global Psychedelic Drugs Market- By Oral, By Value (USD Million), 2016-2026
Figure 17: Global Psychedelic Drugs Market- By Intranasal, By Value (USD Million), 2016-2026
Figure 18: Global Psychedelic Drugs Market- By Intravenous, By Value (USD Million), 2016-2026
Figure 19: Global Psychedelic Drugs Market- By Others, By Value (USD Million), 2016-2026
Figure 20: Global Psychedelic Drugs Market, By Drug, 2020, 2026
Figure 21: Global Psychedelic Drugs Market- By Gamma-hydroxybutyrate, By Value (USD Million), 2016-2026
Figure 22: Global Psychedelic Drugs Market- By Ketamine, By Value (USD Million), 2016-2026
Figure 23: Global Psychedelic Drugs Market- By Psilocybin, By Value (USD Million), 2016-2026
Figure 24: Global Psychedelic Drugs Market- By MDMA, By Value (USD Million), 2016-2026
Figure 25: Global Psychedelic Drugs Market- By Others, By Value (USD Million), 2016-2026
Figure 26: Global Psychedelic Drugs Market, By Distribution Channel, 2020, 2026
Figure 27: Global Psychedelic Drugs Market- By Hospitals Pharmacy, By Value (USD Million), 2016-2026
Figure 28: Global Psychedelic Drugs Market- By Retail Pharmacy, By Value (USD Million), 2016-2026
Figure 29: Global Psychedelic Drugs Market- By Online Pharmacy, By Value (USD Million), 2016-2026
Figure 30: Global Psychedelic Drugs Market, By Region, 2020, 2026
Figure 31: North America Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 32: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 33: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 34: North America Domestic Private Health Expenditure as % of Current Health Expenditure, 2015 - 2018 (In %)
Figure 35: North America Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 36: North America Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 37: North America Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 38: Market Opportunity Chart of North America Psychedelic Drugs Market By Country, By Value, (Year-2026)
Figure 39: North America Psychedelic Drugs Market, By Country, 2020, 2026
Figure 40: United States Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 41: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 42: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 43: United States Mental Illness Prevalence, in 2019, in USD Million
Figure 44: Percentage of U.S. adults with a major depressive episode in the past year as of 2019, by age and gender
Figure 45: United States Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 46: United States Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 47: United States Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 48: Canada Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 49: Healthcare Expenditure, as a percentage of GDP, Canada, 2019
Figure 50: Canada Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 51: Percentage of Canadians who had been diagnosed with anxiety by a medical professional as of 2018, by age
Figure 52: Number of Incident Parkinson Disease cases , in Canada, 2007 - 2017
Figure 53: Canada Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 54: Canada Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 55: Canada Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 56: Europe Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 57: Europe Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 58: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 59: Pharmaceutical market value in top ten European countries in 2018, (in million euros)
Figure 60: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 61: Europe Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 62: Europe Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 63: Europe Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 64: Market Opportunity Chart of Europe Psychedelic Drugs Market- By Country, By Value (Year-2026)
Figure 65: Europe Psychedelic Drugs Market, By Country, 2020, 2026
Figure 66: Germany Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 67: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 68: Germany Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 69: Germany Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 70: Germany Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 71: Germany Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 72: United Kingdom Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 73: United Kingdom Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 74: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 75: Value size of the digital health industry in the United Kingdom (UK) in 2014 and 2018, (in million GBP)
Figure 76: Market Share of Top Pharma Companies in United Kingdom, in 2018
Figure 77: Number of users of headache remedies and pain relief in UK from 2015 to 2019, by user type, (in thousands)
Figure 78: Number of Hospital Admissions due to smoking, in United Kingdom, (in thousands)
Figure 79: United Kingdom Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 80: United Kingdom Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 81: United Kingdom Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 82: France Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 83: Total revenue of the French drug market from 2010 to 2019, in maker pre-tax price, (in million euros)
Figure 84: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 85: France Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 86: France Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 87: France Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 88: Italy Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 89: Public Health Expenditure, in Italy, 2015 - 2019, (Euro Million)
Figure 90: Number of Individuals with Chronic Disease, By Type, 2018, (1000 Individuals)
Figure 91: Annual growth rate of the pharmaceutical market in Italy from 2017 to 2022
Figure 92: Italy Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 93: Italy Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 94: Italy Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 95: Italy Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 96: Spain Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 97: Pharmaceutical Spending (USD Per Capita), in Spain, 2016 - 2019
Figure 98: Number of pharmacies in Spain from 2007 to 2019
Figure 99: Spain Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 100: Spain Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 101: Spain Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 102: Asia Pacific Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 103: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 104: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 105: Projected Pharmaceuticals Sales, in USD Billion, in selected Asia Pacific countries
Figure 106: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 107: Asia Pacific Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 108: Asia Pacific Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 109: Asia Pacific Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 110: Market Opportunity Chart of Asia Pacific Psychedelic Drugs Market- By Country, By Value (Year-2026)
Figure 111: Asia Pacific Psychedelic Drugs Market, By Country, 2020, 2026
Figure 112: China Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 113: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 114: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 115: China Online Healthcare Market in RMB Billions
Figure 116: Market Size of Biotech in China, from 2010 - 2018, in RMB Billion
Figure 117: China Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 118: China Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 119: China Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 120: India Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 121: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 122: India Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 123: India Healthcare Sector Revenue Share
Figure 124: Sale of India Pharma Companies in Dec 2019, (Rs Crore)
Figure 125: Number of cases of Alzheimer's disease in senior citizens across India from 2011 to 2050, (in million)
Figure 126: Increasing Geriatric Population, in percentage population, in India
Figure 127: India Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 128: India Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 129: India Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 130: Japan Psychedelic Drugs Market Size, By Value, 2016-2026 (USD Million)
Figure 131: Japan Median Age of population from 2010 to 2050 (in years)
Figure 132: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 133: Japan Psychedelic Drugs Market- By Drug, By Value (USD Million), 2016-2026
Figure 134: Japan Psychedelic Drugs Market- By Route of Administration, By Value (USD Million), 2016-2026
Figure 135: Japan Psychedelic Drugs Market- By Distribution Channel, By Value (USD Million), 2016-2026
Figure 136: Market Attractiveness Chart of Global Psychedelic Drugs Market - By Drug, By Value (Year 2026)
Figure 137: Market Attractiveness Chart of Global Psychedelic Drugs Market - By Route of Administration, By Value (Year 2026)
Figure 138: Market Attractiveness Chart of Global Psychedelic Drugs Market - By Distribution Channel, By Value (Year 2026)
Figure 139: Market Attractiveness Chart of Global Psychedelic Drugs Market By Region, By Value, (Year-2026)
Figure 140: Global Psychedelic Drugs company market share (%), 2020
Figure 141: Johnson & Johnson Annual Sales Revenue (USD Million), 2016-2020
Figure 142: Johnson & Johnson Annual Net Income/Loss (USD Million), 2016-2020
Figure 143: Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020
Figure 144: Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020
Figure 145: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 146: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 147: Pfizer Sales Revenue Split, By Geography Segment (%), FY2018 - 2020
Figure 148: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 149: AbbVie Inc. Annual Net Income/Loss (USD Million), 2016-2020
Figure 150: AbbVie Inc. Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 151: AbbVie Inc. Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 152: Jazz Pharmaceuticals Annual Sales Revenue (USD Million), 2015-2019
Figure 153: Jazz Pharmaceuticals Annual Net Income/Loss (USD Million), 2015-2019
Figure 154: Jazz Pharmaceuticals Sales Revenue Split, By Product Segment (USD Million), FY2018 - 2019
Figure 155: NUMINUS WELLNESS INC WS Annual Sales Revenue (USD Thousand), 2019-2020
Figure 156: NUMINUS WELLNESS INC WS Annual Net Income/Loss (USD Thousand), 2019-2020
List of Tables
Table A: Current and Potential competitors with a focus on psychedelic assisted psychotherapy
Table B: Psychedelic Breakthrough Therapy Designations (BTD)
Table C: Psychedelic Compounds - Legal Status
Table D: Focused Active Ingredients & Target Markets
Table E: Prominent Psychedelic Drugs Companies operating in North America
Table F: Prominent Psychedelic Drugs Companies operating in Europe
Table G: Prominent Psychedelic Drugs companies operating in Asia Pacific
Table H: Potential Health Care Savings By Psychedelic Medicines , in USA and Europe in (USD Billion)
Table I: Select Psychedelic Clinical Trials
Companies Mentioned
- Johnson & Johnson
- Pfizer
- AbbVie Inc.
- Jazz Pharmaceuticals
- NUMINUS WELLNESS INC WS
- COMPASS Pathways PLC
- Mindset Pharma
- Mydecine Innovations Group
- TRYP Therapeutics Inc
- MindMed
- Cybin Inc.
Table Information
| Report Attribute | Details |
|---|---|
| Published | May 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value in 2021 | 4.07 Billion |
| Forecasted Market Value by 2026 | 7.58 Billion |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
